225 related articles for article (PubMed ID: 34151238)
1. Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia.
Zee BM; Poels KE; Yao CH; Kawabata KC; Wu G; Duy C; Jacobus WD; Senior E; Endress JE; Jambhekar A; Lovitch SB; Ma J; Dhall A; Harris IS; Blanco MA; Sykes DB; Licht JD; Weinstock DM; Melnick A; Haigis MC; Michor F; Shi Y
iScience; 2021 Jun; 24(6):102651. PubMed ID: 34151238
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
Przespolewski A; Wang ES
Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
[TBL] [Abstract][Full Text] [Related]
3. LSD1 inhibition modulates transcription factor networks in myeloid malignancies.
Hartung EE; Singh K; Berg T
Front Oncol; 2023; 13():1149754. PubMed ID: 36969082
[TBL] [Abstract][Full Text] [Related]
4. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.
Cusan M; Cai SF; Mohammad HP; Krivtsov A; Chramiec A; Loizou E; Witkin MD; Smitheman KN; Tenen DG; Ye M; Will B; Steidl U; Kruger RG; Levine RL; Rienhoff HY; Koche RP; Armstrong SA
Blood; 2018 Apr; 131(15):1730-1742. PubMed ID: 29453291
[TBL] [Abstract][Full Text] [Related]
5. Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia.
Magliulo D; Bernardi R; Messina S
Front Oncol; 2018; 8():255. PubMed ID: 30073149
[TBL] [Abstract][Full Text] [Related]
6. Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia.
Deb G; Wingelhofer B; Amaral FMR; Maiques-Diaz A; Chadwick JA; Spencer GJ; Williams EL; Leong HS; Maes T; Somervaille TCP
Leukemia; 2020 May; 34(5):1266-1277. PubMed ID: 31780813
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.
Schenk T; Chen WC; Göllner S; Howell L; Jin L; Hebestreit K; Klein HU; Popescu AC; Burnett A; Mills K; Casero RA; Marton L; Woster P; Minden MD; Dugas M; Wang JC; Dick JE; Müller-Tidow C; Petrie K; Zelent A
Nat Med; 2012 Mar; 18(4):605-11. PubMed ID: 22406747
[TBL] [Abstract][Full Text] [Related]
8. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
Zhang S; Liu M; Yao Y; Yu B; Liu H
Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells.
Fang J; Ying H; Mao T; Fang Y; Lu Y; Wang H; Zang I; Wang Z; Lin Y; Zhao M; Luo X; Wang Z; Zhang Y; Zhang C; Xiao W; Wang Y; Tan W; Chen Z; Lu C; Atadja P; Li E; Zhao K; Liu J; Gu J
Oncotarget; 2017 Oct; 8(49):85085-85101. PubMed ID: 29156705
[TBL] [Abstract][Full Text] [Related]
10. Loss of Kat2a enhances transcriptional noise and depletes acute myeloid leukemia stem-like cells.
Domingues AF; Kulkarni R; Giotopoulos G; Gupta S; Vinnenberg L; Arede L; Foerner E; Khalili M; Adao RR; Johns A; Tan S; Zeka K; Huntly BJ; Prabakaran S; Pina C
Elife; 2020 Jan; 9():. PubMed ID: 31985402
[TBL] [Abstract][Full Text] [Related]
11. Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia.
Maiques-Diaz A; Spencer GJ; Lynch JT; Ciceri F; Williams EL; Amaral FMR; Wiseman DH; Harris WJ; Li Y; Sahoo S; Hitchin JR; Mould DP; Fairweather EE; Waszkowycz B; Jordan AM; Smith DL; Somervaille TCP
Cell Rep; 2018 Mar; 22(13):3641-3659. PubMed ID: 29590629
[TBL] [Abstract][Full Text] [Related]
12. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
Murray-Stewart T; Woster PM; Casero RA
Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
[TBL] [Abstract][Full Text] [Related]
13. Surface antigen-guided CRISPR screens identify regulators of myeloid leukemia differentiation.
Wang E; Zhou H; Nadorp B; Cayanan G; Chen X; Yeaton AH; Nomikou S; Witkowski MT; Narang S; Kloetgen A; Thandapani P; Ravn-Boess N; Tsirigos A; Aifantis I
Cell Stem Cell; 2021 Apr; 28(4):718-731.e6. PubMed ID: 33450187
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.
Sykes DB; Kfoury YS; Mercier FE; Wawer MJ; Law JM; Haynes MK; Lewis TA; Schajnovitz A; Jain E; Lee D; Meyer H; Pierce KA; Tolliday NJ; Waller A; Ferrara SJ; Eheim AL; Stoeckigt D; Maxcy KL; Cobert JM; Bachand J; Szekely BA; Mukherjee S; Sklar LA; Kotz JD; Clish CB; Sadreyev RI; Clemons PA; Janzer A; Schreiber SL; Scadden DT
Cell; 2016 Sep; 167(1):171-186.e15. PubMed ID: 27641501
[TBL] [Abstract][Full Text] [Related]
15. LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
Barth J; Abou-El-Ardat K; Dalic D; Kurrle N; Maier AM; Mohr S; Schütte J; Vassen L; Greve G; Schulz-Fincke J; Schmitt M; Tosic M; Metzger E; Bug G; Khandanpour C; Wagner SA; Lübbert M; Jung M; Serve H; Schüle R; Berg T
Leukemia; 2019 Jun; 33(6):1411-1426. PubMed ID: 30679800
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic drug library screening identified an LSD1 inhibitor to target UTX-deficient cells for differentiation therapy.
Wu B; Pan X; Chen X; Chen M; Shi K; Xu J; Zheng J; Niu T; Chen C; Shuai X; Liu Y
Signal Transduct Target Ther; 2019; 4():11. PubMed ID: 31044091
[TBL] [Abstract][Full Text] [Related]
17. Evolving insights on histone methylome regulation in human acute myeloid leukemia pathogenesis and targeted therapy.
Boila LD; Sengupta A
Exp Hematol; 2020 Dec; 92():19-31. PubMed ID: 32950598
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of EZH2 and G9A/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells.
Sbirkov Y; Schenk T; Kwok C; Stengel S; Brown R; Brown G; Chesler L; Zelent A; Fuchter MJ; Petrie K
Front Cell Dev Biol; 2023; 11():1076458. PubMed ID: 37035245
[TBL] [Abstract][Full Text] [Related]
19. HMG20B stabilizes association of LSD1 with GFI1 on chromatin to confer transcription repression and leukemia cell differentiation block.
Maiques-Diaz A; Nicosia L; Basma NJ; Romero-Camarero I; Camera F; Spencer GJ; Amaral FMR; Simeoni F; Wingelhofer B; Williamson AJK; Pierce A; Whetton AD; Somervaille TCP
Oncogene; 2022 Oct; 41(44):4841-4854. PubMed ID: 36171271
[TBL] [Abstract][Full Text] [Related]
20. Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation.
Ravasio R; Ceccacci E; Nicosia L; Hosseini A; Rossi PL; Barozzi I; Fornasari L; Zuffo RD; Valente S; Fioravanti R; Mercurio C; Varasi M; Mattevi A; Mai A; Pavesi G; Bonaldi T; Minucci S
Sci Adv; 2020 Apr; 6(15):eaax2746. PubMed ID: 32284990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
